Cardiac Marker Testing Market, By Disease (Ischemia, Atherosclerosis, Acute Coronary Syndrome, Congestive Heart Failure, and Myocardial Infarction), By Biomarker Type, By Product, By End Use, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
AV5002
|
Published Date
April 2026
|
Pages
303
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Cardiac Marker Testing Market size was valued at US$ 5,302.18 Million in 2025, expanding at a CAGR of 10.22% from 2026 to 2033.
Cardiac markers are essential tools for assessing and managing patients suspected of acute coronary syndrome (ACS). Common tests include Troponin I and T, high-sensitivity C-reactive protein (hs-CRP), myoglobin, and CK-MB. These markers—comprising hormones, enzymes, and proteins—are released into the bloodstream when the heart experiences stress or damage. Physicians use these tests to monitor changes in blood levels, evaluate the severity of a heart attack, and guide treatment decisions.
The cardiac marker testing market encompasses diagnostic assays that detect biomarkers associated with cardiovascular diseases, including troponins, creatine kinase-MB, and B-type natriuretic peptides. These tests are critical for early detection, risk assessment, and management of conditions such as myocardial infarction and heart failure. Early testing allows clinicians to intervene promptly, improving patient outcomes and reducing complications. For context, screening and early detection play a vital role in managing preventable health risks. For example, a 2026 report by Cancer.org highlighted that approximately 44% of the estimated 626,000 cancer deaths in the United States are potentially preventable, linked to modifiable risk factors such as smoking, obesity, and physical inactivity. Early detection programs can save thousands of lives annually by identifying diseases at stages when treatment is most effective, illustrating the broader impact of timely diagnostic testing.
Cardiac Marker Testing Market- Market Dynamics
Rising Prevalence of Cardiovascular Diseases to Boost Market Demand
The global prevalence of cardiovascular diseases (CVDs) is steadily increasing, with conditions such as heart attacks, strokes, and heart failure becoming more common. This rising incidence is driving the demand for early diagnosis and effective patient monitoring. According to the World Health Organization (WHO), CVDs are the leading cause of death worldwide, responsible for approximately 17.9 million deaths each year. Cardiac marker tests, including troponin, CK-MB, and myoglobin, play a critical role in the early detection, diagnosis, and monitoring of acute coronary events. For example, in July 2025, the WHO reported that in 2021, cardiovascular diseases accounted for an estimated 17.9 million deaths, representing 32% of all global deaths, primarily due to heart attacks and strokes. Notably, over 75% of these deaths occurred in low- and middle-income countries, highlighting significant disparities in global health outcomes. The high prevalence and mortality associated with CVDs underscore the essential role of cardiac marker testing in enabling timely detection and effective management of these conditions.
Cardiac Marker Testing Market- Segmentation Analysis:
The Global Cardiac Marker Testing Market is segmented on the basis of Disease, Biomarker Type, Product, End Use, and Region.
The cardiac marker testing market is segmented by disease into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and ischemia. Among these, myocardial infarction dominates the market due to the critical need for early detection and precise diagnosis. The routine use of cardiac marker tests for monitoring and guiding treatment further reinforces its leading position. For example, in 2025, Becton, Dickinson and Company (BD) enhanced cardiac diagnostics with its BD Vacutainer Troponin I Ultra test, designed for rapid troponin detection to support the diagnosis of acute myocardial infarction in point-of-care settings. The rising prevalence of cardiovascular diseases, combined with continuous innovations in diagnostic technologies, is driving sustained demand for cardiac marker testing in the effective management of myocardial infarction.
The Reagents & Kits segment is also experiencing strong growth, driven by the increasing need for sensitive and specific testing solutions in clinical laboratories. These products enable accurate detection of cardiac biomarkers, supporting reliable diagnosis and ongoing monitoring of cardiovascular conditions. For instance, in December 2025, a report by NIH Gov. highlighted a scoping review of point-of-care (PoC) diagnostic devices in India’s primary healthcare system, identifying 145 relevant records, with 9 studies included after detailed screening. One study using the AideSmart! PoC platform reported a 91.6% completion rate for antenatal screenings among rural women, demonstrating the cost- and time-efficiency of mobile health clinics for community-based non-communicable disease screening. These findings underscore the growing importance of reagents and kits in ensuring accurate diagnostics and expanding access to essential health screening services.
Cardiac Marker Testing Market- Geographical Insights
Geographically, the cardiac marker testing market is influenced by variations in healthcare infrastructure, income levels, government initiatives, and regional disease prevalence. North America continues to hold a significant market share, while the Asia-Pacific region is expected to experience rapid expansion. For example, in September 2025, the U.S. government outlined plans to negotiate multi-year bilateral health agreements with partner countries. These agreements aim to cover 100% of frontline healthcare worker funding and essential health commodities during the agreement period, while gradually shifting long-term responsibilities to recipient nations. The strategy seeks to establish bilateral agreements with most U.S. aid recipients by early 2026, replacing open-ended aid with co-investment models and enhanced global outbreak surveillance.
The Asia-Pacific market is projected to see substantial revenue growth over the forecast period, driven by the rising prevalence of cardiovascular diseases and the increasing need for accurate diagnostic tools. Growing awareness of early detection and timely treatment is boosting demand for cardiac marker tests. Additionally, higher healthcare spending and expanding infrastructure—including new hospitals and diagnostic centers—are supporting market development. For instance, on January 6, 2023, Pathkind Labs, in collaboration with Roche Diagnostics, launched a new cardiac biomarker test, NT-proBNP, aimed at detecting heart failure and supporting the management of Type 2 Diabetes (T2DM). Overall, increasing disease prevalence, heightened awareness, improving healthcare infrastructure, and innovative diagnostic solutions are key factors driving growth in the Asia-Pacific cardiac marker testing market.
Europe Cardiac Marker Testing Market- Country Insights
Europe maintains a stable position in the cardiac marker testing market, driven by the increasing prevalence of cardiovascular diseases, rising healthcare expenditure, and growing demand for point-of-care testing devices. The region’s well-developed healthcare infrastructure facilitates the adoption of advanced diagnostic technologies, supporting overall market growth. For example, in 2025, bioMérieux expanded its portfolio of cardiac biomarker diagnostic solutions for use in acute care settings, enabling rapid detection of myocardial injury and addressing the rising need for effective diagnostics amid increasing cardiovascular disease incidence. Consequently, the combination of a growing cardiovascular disease burden, robust healthcare infrastructure, and ongoing advancements in diagnostic technologies is sustaining the growth of the cardiac marker testing market in Europe.
Cardiac Marker Testing Market- Competitive Landscape:
The global cardiac marker testing market is highly fragmented, with a mix of large and mid-sized players accounting for the majority of market revenue. Key companies, including Hoffmann-La Roche Ltd, Abbott, Siemens Healthcare GmbH, and Danaher, are leveraging strategies such as mergers and acquisitions, strategic partnerships, and new product launches to expand their market presence. For example, in January 2025, Roche announced that its Roche Digital Pathology Dx whole slide imaging system received U.S. FDA approval for use with the VENTANA DP 600 slide scanner. This regulatory clearance strengthens Roche’s digital pathology capabilities, enhancing diagnostic accuracy and workflow efficiency in clinical laboratories. Ongoing strategic initiatives and regulatory approvals by leading players are expected to drive innovation and competitive growth in the cardiac marker testing market.
Recent Developments:
- In 2025, Siemens Healthcare GmbH expanded its cardiac diagnostics portfolio with the Atellica IM High-Sensitivity Troponin I (TnIH) assay, enabling rapid detection of myocardial infarction while providing prognostic insights for future cardiac events. This supports early diagnosis and risk stratification for patients with suspected acute coronary syndromes.
- On January 3, 2025, Abbott collaborated with healthcare providers through its point-of-care network following U.S. FDA clearance of the i-STAT high-sensitivity troponin-I (hs-TnI) cartridge. The device allows rapid bedside assessment of patients with suspected myocardial infarction and strengthens clinical partnerships for improved cardiac diagnostics and patient management.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CARDIAC MARKER TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- bioMérieux SA
- Danaher Corporation
- Fujirebio
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Beckman Coulter, Inc.
- QuidelOrtho
- Randox Laboratories Ltd.
- Tosoh Corporation
- Mindray Medical International Limited
- Others
GLOBAL CARDIAC MARKER TESTING MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Ischemia
- Atherosclerosis
- Acute Coronary Syndrome
- Congestive Heart Failure
- Myocardial Infarction
GLOBAL CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2020 - 2033
- Myoglobin
- High-Sensitivity C-Reactive Protein (HSCRP)
- Troponin I and T
- Natriuretic Peptide (BNP and NT-proBNP)
- Creatine Kinase–MB (CK-MB)
- Others
GLOBAL CARDIAC MARKER TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- Instruments
- Reagents & Kits
GLOBAL CARDIAC MARKER TESTING MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Point-of-Care Testing Facilities
- Academic Institutes
- Laboratory Testing Facilities
GLOBAL CARDIAC MARKER TESTING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Cardiac Marker Testing Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Cardiac Marker Testing Market Snippet by Disease
2.1.2. Cardiac Marker Testing Market Snippet by Biomarker Type
2.1.3. Cardiac Marker Testing Market Snippet by Product
2.1.4. Cardiac Marker Testing Market Snippet by End Use
2.1.5. Cardiac Marker Testing Market Snippet by Country
2.1.6. Cardiac Marker Testing Market Snippet by Region
2.2. Competitive Insights
3. Cardiac Marker Testing Key Market Trends
3.1. Cardiac Marker Testing Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Cardiac Marker Testing Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Cardiac Marker Testing Market Opportunities
3.4. Cardiac Marker Testing Market Future Trends
4. Cardiac Marker Testing Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Cardiac Marker Testing Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Cardiac Marker Testing Market Landscape
6.1. Cardiac Marker Testing Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Cardiac Marker Testing Market – By Disease
7.1. Overview
7.1.1. Segment Share Analysis, By Disease, 2025 (%)
7.1.2. Ischemia
7.1.3. Atherosclerosis
7.1.4. Acute Coronary Syndrome
7.1.5. Congestive Heart Failure
7.1.6. Myocardial Infarction
8. Cardiac Marker Testing Market – By Biomarker Type
8.1. Overview
8.1.1. Segment Share Analysis, By Biomarker Type, 2025 & 2033 (%)
8.1.2. Myoglobin
8.1.3. High-Sensitivity C-Reactive Protein (HSCRP)
8.1.4. Troponin I and T
8.1.5. Natriuretic Peptide (BNP and NT-proBNP)
8.1.6. Creatine Kinase–MB (CK-MB)
8.1.7. Others
9. Cardiac Marker Testing Market – By Product
9.1. Overview
9.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
9.1.2. Instruments
9.1.3. Reagents & Kits
10. Cardiac Marker Testing Market – By End Use
10.1. Overview
10.1.1. Segment Share Analysis, By Biomarker Type, 2025 & 2033 (%)
10.1.2. Point-of-Care Testing Facilities
10.1.3. Academic Institutes
10.1.4. Laboratory Testing Facilities
11. Cardiac Marker Testing Market – By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
11.2. North America
11.2.1. Overview
11.2.2. Cardiac Marker Testing Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.2.4. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.2.5. North America Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.2.6. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.2.7. North America Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. Cardiac Marker Testing Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.5. Europe Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.10.4. France Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. Cardiac Marker Testing Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.5. APAC Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.8.4. China Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.9.4. India Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. Cardiac Marker Testing Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. Cardiac Marker Testing Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.5. MEA Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By Biomarker Type, 2020 - 2033 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End Use, 2020 - 2033 (US$ Million)
12. Key Vendor Analysis- Cardiac Marker Testing Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Abbott Laboratories
12.2.2. bioMérieux SA
12.2.3. Danaher Corporation
12.2.4. Fujirebio
12.2.5. F. Hoffmann-La Roche Ltd.
12.2.6. Siemens Healthineers AG
12.2.7. Beckman Coulter, Inc.
12.2.8. QuidelOrtho
12.2.9. Randox Laboratories Ltd.
12.2.10. Tosoh Corporation
12.2.11. Mindray Medical International Limited
12.2.12. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CARDIAC MARKER TESTING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Abbott Laboratories
- bioMérieux SA
- Danaher Corporation
- Fujirebio
- F. Hoffmann-La Roche Ltd.
- Siemens Healthineers AG
- Beckman Coulter, Inc.
- QuidelOrtho
- Randox Laboratories Ltd.
- Tosoh Corporation
- Mindray Medical International Limited
- Others
GLOBAL CARDIAC MARKER TESTING MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Ischemia
- Atherosclerosis
- Acute Coronary Syndrome
- Congestive Heart Failure
- Myocardial Infarction
GLOBAL CARDIAC MARKER TESTING MARKET, BY BIOMARKER TYPE- MARKET ANALYSIS, 2020 - 2033
- Myoglobin
- High-Sensitivity C-Reactive Protein (HSCRP)
- Troponin I and T
- Natriuretic Peptide (BNP and NT-proBNP)
- Creatine Kinase–MB (CK-MB)
- Others
GLOBAL CARDIAC MARKER TESTING MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- Instruments
- Reagents & Kits
GLOBAL CARDIAC MARKER TESTING MARKET, BY END USE- MARKET ANALYSIS, 2020 - 2033
- Point-of-Care Testing Facilities
- Academic Institutes
- Laboratory Testing Facilities
GLOBAL CARDIAC MARKER TESTING MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
